Compare PBYI & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBYI | AGD |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 309.7M |
| IPO Year | 2011 | 2006 |
| Metric | PBYI | AGD |
|---|---|---|
| Price | $7.61 | $12.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 370.3K | 121.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.78 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $27,685,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $8.46 |
| 52 Week High | $7.68 | $13.98 |
| Indicator | PBYI | AGD |
|---|---|---|
| Relative Strength Index (RSI) | 69.82 | 56.50 |
| Support Level | $6.32 | $11.15 |
| Resistance Level | N/A | $12.88 |
| Average True Range (ATR) | 0.29 | 0.21 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 93.89 | 56.80 |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.